A strategy for risk mitigation of antibodies with fast clearance.
about
Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactionsAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging.Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design.Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturationImpact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data.Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance.Preclinical development of AMG 139, a human antibody specifically targeting IL-23In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability.A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions.Characterization and screening of IgG binding to the neonatal Fc receptor.Antibody engineering for increased potency, breadth and half-life.Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.A High Through-put Platform for Recombinant Antibodies to Folded Proteins.High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in miceBalancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokineticsFramework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.Tuning the specificity of a Two-in-One Fab against three angiogenic antigens by fully utilizing the information of deep mutational scanning.Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey PharmacokineticsPreclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeysBiophysical properties of the clinical-stage antibody landscape.Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.Engineering broadly neutralizing antibodies for HIV prevention and therapy.High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Incorporation of FcRn-mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients.Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo.Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.Therapeutic Antibody-Induced Vascular Toxicity Due to Off-Target Activation of Nitric Oxide in Cynomolgus Monkeys.Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration.Target-independent variable region mediated effects on antibody clearance can be FcRn independent.Use of generic LC-MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody.An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies.An automated immunoassay for early specificity profiling of antibodiesEffects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeysPharmacokinetics of Monoclonal Antibodies.
P2860
Q27002558-97C7D9EE-3040-49F5-8E28-A9C87C0AEACEQ30275229-2F00687D-F542-4C04-B55E-AA86DC20B3DFQ30364628-CCAC1DD2-A5F4-4A39-8780-000B9768FECEQ30383551-B23A0D8A-5ACA-42CC-9DD3-CF1E9358EAA6Q31091923-4BC0BE9D-93A3-4148-A5A8-BA0240BFF317Q31149925-DD66B641-DABD-4613-A361-095E761682E3Q31150455-23DD2682-7D3E-4760-BFD7-7A642C02EA41Q33635071-F9C445AA-6FAF-4A69-ABF3-D6DD3280DE23Q34795742-86A73D9F-52C1-4F9F-9965-E8E3E1FF4C4BQ34831383-F912FF04-BF6B-4916-8B5C-24D2F2583255Q35117636-F7750FCF-7FC3-4264-9596-B54E0C978BF8Q35163945-DEFCC2DB-A118-474B-98E9-AC411842F4DFQ35575206-59EBFE85-2707-47C2-B260-B6E8FD0336F8Q35856534-9107925B-1E13-4CE3-8B8F-38691F029DE7Q36134059-DE0F9648-8B09-46C6-B9E5-7254565388A7Q36213701-4D08C2B6-9D5D-4D4B-8CE6-480EBD1D61EBQ36214515-2F2412AD-5089-4DBF-9073-B22D241ACB25Q36215733-465F86E3-FEA3-400E-9C73-CBCA8654830FQ36393842-B3879BC6-8F55-4668-8625-C2714951BAF4Q36444225-2AD549B8-43FE-4816-87EC-D0C3BF06AB65Q37138952-05C34EBB-874E-41FF-9E05-780317A9A8F0Q37141605-13F651CA-2F37-464D-98E1-96A6154FA620Q37626251-7AAC106F-CCDC-4F8D-B574-8D619A720A07Q38587550-FF5E6C51-1B16-4800-9BAD-20C0A4927D2CQ38717198-C7D5F98F-39B9-4E5A-9908-1B38A03A496EQ38718094-68128E85-CC1F-4B75-B155-9909E86B3853Q38821056-A986E4E6-754A-4C8C-9A03-22B33604DD4DQ38831148-A4CC5163-4930-40B2-A5B7-EBEF29865A75Q38941467-0146A7B0-083F-4A09-8C1F-7D5DECAA31C0Q39277950-55652560-A0E3-4479-9E10-CD43E5F1B218Q39496098-9A66C220-B78D-482F-9884-7962C8B1D41CQ39731345-D7439B43-5635-4C36-99CD-3BD9E2955ED6Q39966848-7A429EF3-FE91-4A50-BB80-05FFD82DB35EQ40822573-10856104-C879-486A-ABE0-9D5117950EBAQ41416019-4DB7503C-03E7-47C3-9374-981ED7BCBA66Q41662108-734C5826-DDB7-4198-8C07-BF032BAF3150Q41845586-1D517F59-DC2C-4D85-A9F2-EE8E4AC1E285Q41874335-644A5D3D-4078-4875-A20B-CF5E52B72A8FQ41880655-29CA5412-55F1-476B-B664-E5D229B8B156Q42118646-6A3D2B1E-6D1D-408F-9A7C-C73A5501CB93
P2860
A strategy for risk mitigation of antibodies with fast clearance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A strategy for risk mitigation of antibodies with fast clearance.
@en
type
label
A strategy for risk mitigation of antibodies with fast clearance.
@en
prefLabel
A strategy for risk mitigation of antibodies with fast clearance.
@en
P2093
P2860
P356
P1476
A strategy for risk mitigation of antibodies with fast clearance
@en
P2093
Daniela Bumbaca
Frank-Peter Theil
Jeff Lutman
Leah Quintana
Lisa J Bernstein
Pamela Chan
Paul Fielder
Paul J Carter
Renuka Sibia
Robert F Kelley
P2860
P304
P356
10.4161/MABS.22189
P50
P577
2012-11-01T00:00:00Z